Press release content from Newswire. The AP news staff was not involved in its creation.
DLP Real Estate Capital Acquires Multifamily Portfolio of 1,086 Apartment Units Along the Gulf Coast
March 16, 2021 GMT
DLP Real Estate Capital Acquires Multifamily Portfolio of 1,086 Apartment Units Along the Gulf Coast
DLP Real Estate Capital Acquires Multifamily Portfolio of 1,086 Apartment Units Along the Gulf Coast
ST. AUGUSTINE, Fla. - March 16, 2021 - ( Newswire.com )
DLP Real Estate Capital announced its acquisition of the PROSPER Gulf Coast portfolio, a multifamily property portfolio, consisting of four communities along the gulf coasts of Mississippi and Alabama. This 1,086-unit portfolio will greatly impact individuals and families living in these localities as DLP will provide them with affordable and safe, workforce housing.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical .
OSE ImmunotherapeuticsMarch 15, 2021 GMT This clinical trial will be sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and OSE Immunotherapeutics.
The study will explore Tedopi®’s potential in an additional oncology indication with significant unmet medical need.
NANTES, France, March 15, 2021 (GLOBE NEWSWIRE) OSE Immunotherapeutics (FR0012127173) and the French cooperative group ARCAGY-GINECO today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer (the TED
Press release content from PR Newswire. The AP news staff was not involved in its creation.
VLP Therapeutics raises $16M Series A for cancer treatment vaccine R&D
March 15, 2021 GMT
Logo of VLP Therapeutics
GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and three existing investors in the US (Mr. Robert G. Hisaoka, SK Impact Fund, LLC, and RJ Fund, LLC) for research and development of a cancer treatment vaccine. With this funding, VLPT aims to accelerate the project well underway in the US and move into clinical trials at the earliest date possible.